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Abstract 
Healthy cartilage maintenance relies on an equilibrium among the anabolic and catabolic processes in 
chondrocytes. With the onset of osteoarthritis (OA), increased interleukin (IL)-1β levels induce an inhibition of 
the synthesis of extracellular matrix (ECM) proteins, as well as an increase in proteases. This eventually leads to 
a predominance of the catabolic phenotype and the progressive loss of articular cartilage. Hydrogen sulfide 
(H2S) is a small gaseous molecule recognized as the third endogenous gasotransmitter. When administered 
exogenously, it has shown anti-inflammatory and anti-catabolic properties in several in vitro and in vivo models. 
Here, OA cartilage disks were co-cultured in vitro with IL-1β (5 ng/ml) and NaSH or GYY4137 (200 or 
1000 μM) for 21 days. The ability of these two H2S-producing compounds to avoid long term extracellular 
matrix (ECM) destruction was evaluated. We used a glycosaminoglycan (GAG) quantification kit histology and 
immunohistochemistry (IHC) to evaluate matrix proteins degradation and matrix metalloproteinases (MMP) 
abundance. Through the GAGs quantification assay, safranin O (S-O) and toluidine blue (TB) stains, and 
keratan/chondroitin sulfate (KS/ChS) IHCs it was shown that co-stimulation with H2S-forming reagents 
effectively avoided GAGs destruction. Both Masson's trichrome (MT) stain and collagen (col) type II IHC, as 
well as aggrecan (agg) IHC demonstrated that not only were these proteins protected but even promoted, their 
abundance being higher than in the basal condition. Further, stains also demonstrated that positivity in the inter-
territorial and intra-cellular for the different matrix components were rescued, suggesting that NaSH and 
GYY4137 might also have pro-anabolic effects. In addition, a clear protective effect against the increased MMPs 
levels was seen, since increased MMP3 and 13 levels were subsequently reduced with the co-stimulation with 
sulfide compounds. In general, GYY4137 was more effective than NaSH, and increasing the dose improved the 
results. 
This study demonstrates that H2S anti-catabolic effects, which had been previously proven in short-term (24–
48 h) in vitro cellular models, are maintained over time directly in OA cartilage tissue. 
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Osteoarthritis (OA) is an heterogenous rheumatic disease that affects diarthrodial joints and 
results in pain, loss of mobility and function, and a reduction in quality of life. OA is a silent disease 
in the sense that symptoms appear when it is quite advanced. With OA, articular cartilage, 
responsible for the absorption and transference of loads to the subchondral bone, is progressively lost. 
Since cartilage is mostly avascular and aneural, only when the anatomy of the joint is severely 
deteriorated is the disease manifested, most significantly by joint pain. Thus, cartilage degradation is 
considered the hallmark of OA progression. Cartilage ECM is composed of a dense network of 
collagen (col) type II, glycosaminoglycans (GAGs) and proteoglycans, such as aggrecan (agg). 
Maintenance of this network relies on a balanced metabolic equilibrium in chondrocytes. 
Chondrocyte phenotype can change depending on the physiological or stress conditions [1] and a 
series of different phenotypes have been proposed, namely: 
 
a) A chondroblastic phenotype, expressing the fetal collagen types II and III. 
b) An anabolic phenotype that is able to maintain and regenerate the ECM synthesizing col II and 
proteoglycans. 
c) A catabolic phenotype, in which the expression of proteolytic enzymes is increased in 
response to pro-inflammatory factors such as tumor necrosis factor (TNF)-α, interleukin (IL)-
1β or nitric oxide (NO). 
d) An hypertrophic phenotype, which expresses type X collagen and runt-related transcription 
factor 2 (runx2), among others, characteristic of the deep, mineralized zone of cartilage. 
e) A fibroblastic de-differentiated phenotype, which expresses collagen type I and synthesizes 
fibro-cartilage, as a way to repair damaged tissue. 
 
Under normal conditions, there is a balance between the anabolic and catabolic phenotypes for the 
proper maintenance of adult hyaline cartilage. However, with the development of OA, the catabolic 
phenotype starts to predominate leading to an imbalance between synthesis and degradation of the 
cartilage matrix, in addition to an increase in the hypertrophic and de-differentiated phenotypes, in an 
attempt to repair OA cartilage damage [2]. 
 
Increased catabolism in OA is the result of unnormally elevated levels of metalloproteases. These 
are synthesized by chondrocytes in response to inflammatory stimuli, including IL-1β, TNF-α and 
NO. One of the most relevant metalloprotease families in OA is that of the matrix metalloproteinases 
(MMPs). Among these, collagenase 3 (MMP13) is the most relevant enzyme in terms of col II 
degradation. MMP13, is regulated by stress in general, and inflammation in particular, and it appears 
to play a predominant role in the early stages of OA, suggesting that its inhibition might prevent 
intensification of disease [3]. Additionally, stromelysin 1 (MMP3) activity has been specifically 
linked to proteoglycan loss [4], but it can, in addition, degrade not only col II and agg, but also other 
non-collagenous matrix proteins, and it participates in the activation of different pro-MMP. 
 
Hydrogen sulfide (H2S) is a small gaseous molecule that has been recognized as an endogenous 
gasotransmitter [5,6]. Its discovery in the late 90's as an endogenous signaling molecule in the 
nervous and cardiovascular systems, triggered the research on its mechanisms of action and its effects 
in different pathologies, which hasn't stopped growing since [7–11]. 
 
The study of the functions of H2S in the musculoskeletal system is quite incipient. Yet, it is 
already accepted that it is present and modulated in the osteoarthritic process [12–14] and it exerts 
anti-inflammatory and cytoprotective effects in joint cells at low micromolar doses [12,14,15]. In 
2010, Whiteman et al. showed that H2S is present in the synovial fluid (SF). In patients with 
rheumatoid arthritis, SF H2S levels were significantly and substantially higher than in paired plasma 
samples or SF aspirates from OA patients [14]. Additionally, H2S levels in SF and plasma correlated 
with clinical markers of disease activity and inflammation. Later, the expression of H2S synthesis 
enzymes cystathionine-β-synthase (CBS) and cystathionine-γ-lyase (CTH) was demonstrated in 
chondrocytes and chondrogenically-differentiated mesenchymal stem cells [12]. Lastly, several 
groups including ours have found that exogenous administration of H2S to OA chondrocytes exerts 
anti-inflammatory and anti-catabolic effects after 24–48 h of stimulation [15–17]. Reduced gene 
expression and protein abundance of inflammation mediator such as IL-6, MMP3 and 13, NO or 
prostaglandin E2 was demonstrated. 
 
These studies indicate that not only is H2S present endogenously in the joint, but that in OA 
cartilage exogenous administration can be beneficial. However, only short term effects were assessed 
while cartilage degradation is a long-term process. 
 
Therefore, the aim of the present work was to evaluate the ability of two compounds that produce 
H2S, sodium hydrosulfide (NaSH) and GYY4137 (morpholin-4-ium 4 methoxyphenyl(morpholino 
phosphinodithioate)), to counteract the effects of IL-1β on matrix destruction. In particular, 
experiments were performed to qualitatively and quantitatively assess effects on the principal matrix 
component through tissue histology and immunohistochemistry, and to quantify GAGs destruction in 
cartilage stimulated with IL-1β for 21 days. 
2. Materials and methods 
2.1. Materials 
Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS) and 
Penicillin/streptomycin (P/S, 100units/ml and 100 μg/ml, respectively) were from Gibco (Gibco, 
Madrid, Spain). Culture flasks, well plates and other disposable culture plastic were purchased from 
BD (BD Bioscience, Madrid, Spain). Sodium hydrosulfide (NaSH) and human recombinant IL-1β 
were purchased from Sigma-Aldrich (Sigma-Aldrich Química S.A, Madrid Spain). GYY4137 
(morpholin-4-ium 4 methoxyphenyl(morpholino phosphinodithioate)) was purchased from Santa 
Cruz Biotechnology, Heidelberg, Germany. Antibodies and conditions used for IHC are in Table 1. 
The GAGs quantification assay (Blyscan) was from Scharlab S.L. (Barcelona, Spain). 
Table 1. List and characteristics of the antibodies used in the immunohistochemistry techniques. All were mouse anti-human 
monoclonal antibodies. 
Antibodies Clon Isotype Provider Pretreatment Dilution 
     
Collagen type II 5B2.5 IgG1κ Abcam
® Chondroitinase ABC pH 8.0 1:25 
Chondroitin 6-sulfate CS-56 IgM Abcam® Chondroitinase ABC pH 6.8 1:100 
Aggrecan BC-3 IgG Abcam® Chondroitinase ABC pH 6.8 1:100 
Keratan sulfate 4B3/D10 IgG1 Santa Cruz none 1:100 
Matrix metalloproteinase 3 SL-1 IID4 IgG2b Millipore Chondroitinase ABC pH 6.8 1:25 
Matrix metalloproteinase 13 VIIIA2 IgG1κ Thermo Scientific Proteinase K 1:50 
     
 
Reagents for tissue histology were from either Merck or Sigma-Aldrich, except for alcian blue 
(AB) (Applichem, VWR International Eurolab S.L. Barcelona, Spain) and DePex (Gurr
®
, VWR 
International Eurolab S.L. Barcelona, Spain). Those for immunohistochemistry (IHC) were from 
Dako (Dako, Barcelona, Spain). 
  
2.2. Tissue selection and isolation 
Osteoarthritic cartilage was obtained from samples included in the Sample Collection for 
Research on Rheumatic Disease started by Dr. Francisco Blanco García. This collection was 
authorised by the Galician Research Ethics Committee (Comité Autonómico de Ética da 
Investigación de Galicia, CAEIG) with registry code 2013/107 and has been inscribed in the National 
Registry of Biobanks (Registro Nacional de Biobancos), Collections Section code: C.0000424. 
Informed consent was obtained from all the donors. 
 
Cartilage used in this study was obtained from 1 female and 2 male donors aged 74, 78 and 64, 
respectively, at the time of the surgery. All had been diagnosed with osteoarthritis. 
2.3. Exposure of cartilage to inflammatory mediators 
Cartilage tissue was isolated from femoral heads or condyles, or from tibial plateaus by resection 
with a scalpel. The sheets of cartilage were then cut into discs with a 6 mm biopsy punch, so that 
cartilage discs dimensions were approximately 6 mm in diameter and 2 mm in height. Disks were 
then incubated in a 24 well plate with DMEM containing 5% glutamine (2 mM), 5% P/S, and 10% 
FBS in a humidified incubator with 5% CO2 at 37 °C for 24 h. 
 
Experiments were performed to investigate if co-estimulation with H2S could protect matrix 
components and reduce matrix destruction in cartilage stimulated with IL-1β. For this end, cartilage 
explants (two per condition) were stimulated with 5 ng/ml of IL-1β and NaSH or GYY4137 (200 or 
1000 μM), keeping one unstimulated condition (basal) and one condition with only 5 ng/mL of IL-1β. 
The medium (containing the stimuli) was renewed every 4 days for a total of 21 days. Supernatants 
were collected with each medium change and stored at −80 °C for further analyses. 
 
After the stimulation period, tissue discs were recovered, carefully patted dry with a piece of filter 
paper and weighed. One half of each disc was processed for histology and immunohistochemistry, 
and the other two halves were used for GAGs quantification assays. 
2.4. Glycosaminoglycans release and quantification 
For each condition, total glycosaminoglycans content was quantified by measuring the 
(accumulative) amount released to the supernatants and the remaining amount in the explants. A 
commercial kit, Blyscan sulfated glycosaminoglycans assay, was used for both, tissue and medium 
GAGs quantification, following the protocol described therein. Briefly, for quantification in the 
supernatants, 1 ml of Blyscan dye reagent was added to 100 μl of each sample supernatant (final 
volume including dilutions, if necessary). This was mixed by inversion and tubes were gently shaken 
for 30 min. This causes a sulfated GAG-dye complex to form and precipitate from the solution. 
Tubes were centrifuged 12000 rpm for 10 min and the supernatant discarded. After this, 0.5 ml of 
dissociation reagent was added to the tubes, vortex mixed and centrifuged again at 12000 rpm for 
5 min, to remove foam. Then, 200 μl of each resulting supernatant were transferred to a 96-well plate 
and read at 656 nm in a Nanoquant Infinite M200 spectrophotometer (Tecan). To analyze its GAG 
content the tissue was dehydrated and digested with papain. About 13–15 mg of cartilage tissue per 
sample was digested in 1 ml of papain extraction reagent in a thermoblock at 65 °C overnight. When 
the cartilage was totally digested the solution was centrifuged at 10000 g for 10 min to collect the 
supernatant, the general protocol of the assay was completed and the absorbance also read. Samples 
were compared to a calibration curve prepared with a GAGs standard (bovine tracheal chondroitin 4-
sulfate) provided by the kit. 
  
2.5. Cartilage histology and immunohistochemistry analyses 
For the different studies one half of one disc of cartilage was fixed in 4% paraformaldehyde for 
24 h, dehydrated in graded alcohols (70°, 96° and absolute) and included in paraffin. Paraffin blocks 
were cut in 4 μm sections, deparaffinized (10 min in an oven at 37 °C), rinsed with xylene for 10 min 
and rehydrated in a sequence of decreasing alcohols followed by distilled water. Sections were used 
for tissue histology and for immunohistochemistry. 
 
Cartilage matrix main components were demonstrated with the following stains: 
 
Safranin O (S-O) stain binds to sulfated GAGs such as chondroitin sulfate (ChS) and keratan 
sulfate (KS), so a strong red staining indicates a high amount of sulfated GAGs. Toluidine blue (TB) 
is a basic thiazine metachromatic dye with high affinity for acidic tissue components, and in cartilage 
a purple color indicates a high amount of hyaluronic acid (HA), its most abundant metachromatic 
component. Alcian blue is used to stain acidic glycosaminoglycans, such as chondroitin sulfate (ChS) 
and HA, and the peryodic acid-Schiff (PAS) staining is mainly used for staining structures containing 
a high proportion of carbohydrate macromolecules. In Masson's trichrome (MT) three dyes are 
employed to selectively stain muscle, collagen fibers, fibrin, and erythrocytes. Nuclei appear black, 
cytoplasm, muscle, erythrocytes are stained red and collagen is stained in blue. 
 
In the sections for IHC the appropriate antigen-epitope retrieval pretreatment was performed for 
each antibody (Table 1). Endogenous peroxidase activity was blocked with Dako Real™ peroxidase 
blocking solution for 10 min at room temperature. Cells were then washed with phosphate buffer 
solution (PBS) and incubated with the primary antibody (Table 1). The rabbit/mouse 
peroxidase/DAB DAKO REAL™ EnVision™ detection kit was used to determine antigen–antibody 
interactions. Slides were dehydrated in graded alcohol, cleared in xylene and mounted in DePeX. A 
negative control was included by omitting the primary antibody in one of the sections. All slides were 
then visualized in an Olympus Dx61 optical microscope, and quantified using analySIS D software 
(Olympus España S.A.U., Barcelona, Spain). Proteins selected for the analysis of matrix components 
were col II, ChS, agg, and KS, and those chosen for the analysis of catabolism were MMP3 and 13. 
3. Statistical analysis 
All experiments were performed with tissue from at least two different donors (n ≥ 2) and with 
technical duplicates in the case of the GAGs quantification assay. Quantification values in the 
histology and IHC stains resulted from 3 representative images (20× magnification) obtained in tissue 
from 2 donors, i.e mean of 6 images per condition. The results are expressed as mean ± standard error 
(SE). All the statistical analyses were performed using the R software (version 2.15.2) [18]. Data 
were assayed with analysis of variance (ANOVA) followed via a Tukey test for multiple 
comparisons, except when they failed tests of normality (Shapiro-Wilk's) or homoscedasticity 
(Bartlett test or Levene's). In this case a Kruskal-Wallis rank sum test was performed followed by 
multiple comparisons. In all cases, differences were considered significant when p < 0.05. 
  
4. Results 
4.1. Glycosaminoglycan quantification 
The results of the biochemical quantification of GAGs retained in, and released from cartilage 
stimulated with IL-1β are presented in Fig. 1. In basal conditions after 21 days, 79.9 ± 9.5% of GAGs 
remained in the OA tissue, while 20.1 ± 9.5% was released to the supernatant. As expected, exposure 
to IL-1β for 21 days resulted in a significant decrease in the amount of GAGs in the tissue 
(45.5 ± 1.9%) and a corresponding increase in the amount lost to the supernatant (54.5 ± 1.9%), 
p < 0.05. Interestingly, co-stimulation with the H2S forming compounds resulted in a marked 
improvement in all cases, increasing the amount of GAGs retained in the tissue and protecting or 
inhibiting their loss to the supernatant. The best condition was 200 μM NaSH (70.9 ± 5.1 and 
29.1 ± 5.1, respectively) and none of them were significantly different from either the Basal or the 




Fig. 1. Glycosaminoglycans (GAGs) percentages retained and released into the supernatant in OA cartilage after 21 days of co-
stimulation with IL-1β and NaSH or GYY4137 in vitro. The percentages remaining in the tissue and released into the 
supernatant are shown in dark and clear bars, respectively. 
4.2. Histological stainings 
Representative images of the different histological stains performed are presented in Fig. 2. 
Quantification of the images was performed as explained in the methods. Results are included in 





Fig. 2. Representative images of histological stains performed in OA cartilage after 21 days of co-stimulation with IL-1β and 
NaSH or GYY4137 in vitro. A) Safranin O, B) Toluidine blue, C) Alcian blue – PAS, D) Masson's trichrome. Numbers 
represent the following conditions: 1) Basal, 2) Stimulation with IL-1β only, 3) IL-1β + 200 μM NaSH, 4) IL-1β + 1000 μM 
NaSH, 5) IL-1β + 200 μM GYY4137, 6) IL-1β + 1000 μM GYY4137. In A), B) and D) size bars represent 100 μm, in C, 1 
mm. *p < 0.05 with respect to the condition with IL-1β. 
Table 2. Quantifications for safranin O, toluidine blue, alcian blue-PAS and Masson's trichrome staining performed in 
osteoarthritic cartilage stimulated with IL-1β. *p < 0.05 with respect to the condition with IL-1β only. 
Stain Basal 
All conditions stimulated with IL-1β (5 ng/mL) 
0 μM NaSH  GYY4137 
 
200 μM 1000 μM  200 μM 1000 μM 
        
Safranin O 93.0 ± 3.3* 14.0 ± 2.3 0.6 ± 0.2 79.9 ± 16.2*  83.8 ± 5.7* 89.8 ± 10.2* 
Toluidine blue 98.9 ± 0.3* 65.7 ± 5.0 98.5 ± 1.3* 98.8 ± 2.0*  99.0 ± 3.4* 98.3 ± 3.3* 
Alcian blue PAS 80.1 ± 13.2 
7.8 ± 4.2* 
55.6 ± 18.5 
38.0 ± 8.7 
54.6 ± 8.0 
7.4 ± 8.8* 
70.6 ± 11.8 
10.8 ± 4.1* 
 67.4 ± 18.3 
7.9 ± 2.0* 
66.7 ± 10.1 
8.7 ± 2.9* 
Masson's trichrome 91.0 ± 3.8* 79.8 ± 7.4 90.1 ± 2.1* 90.0 ± 0.2*  90.5 ± 5.8* 92.4 ± 3.0* 
        
 
4.2.1. Safranin O 
S-O staining (Fig. 2A and Table 2) revealed a sharp loss of GAGs due to the cytokine exposure 
from 93.0 ± 3.3 in the basal condition down to 14.0 ± 2.3 in the IL-1β only condition (Fig. 2A1 and 
2A2, respectively). It is also striking that in the basal condition (Fig. 2A1), the inter-territorial region 
surrounding chondrocytes was more positive than the rest of the matrix, suggesting that cells were 
actively producing GAGs, while in the discs stimulated with IL-1β this positivity was lost. GAGs 
were protected when the tissue was co-stimulated with 200 and 1000 μM GYY4137 doses 
(83.8 ± 5.7% and 89.8 ± 10.2%, respectively Fig. 2A5–6), whereas in the case of NaSH only the 
highest concentration exerted this effect (98.5 ± 1.3%, Fig. 2A3–4). Quantitatively, all conditions 
were significantly better than IL-1β (p < 0.05), except for 200 μM NaSH (Table 2).  
4.2.2. Toluidine blue 
In the staining for metachromatic components, represented in cartilage mostly by HA, no 
differences in staining intensity were observed in the superficial layer (not shown), and the effects of 
both IL-1β and the sulfide compounds were more apparent in the deeper layer of cartilage, so we 
opted for showing these areas instead. Staining was reduced from 98.9 ± 0.3 to 65.7 ± 5.0 when OA 
tissue was cultured with IL-1β (Fig. 2B1 vs. 2B2, Table 2). This effect was counteracted by both 
H2S-forming compounds and a concentration of 200 μM of either seemed already fully effective, 
recovering the basal levels (Fig. 2B3–6, Table 2; p < 0.05 vs. IL-1β). Further, the inter-territorial and 
intra-cellular regions that had practically lost their staining with IL-1β, also recovered with NaSH and 
GYY4137 co-estimulation. 
4.2.3. Alcian blue-PAS 
It is noteworthy that there were small areas of intense PAS staining (fuchsia) in the deep zone of 
cartilage (visible in the lower left corners of Fig. 2C1 and 2C6) that were remarkably increased due to 
IL-1β stimulation (7.8 ± 4.2% in basal condition and 38.0 ± 8.7% in IL-1β condition [Fig. 2C2] and 
Table 2). This was not seen in normal cartilage (results not shown). This suggests that there is an 
increased presence of carbohydrates in OA, and that its production is induced by IL-1β. On the other 
hand, we also observed a slight loss of alcian blue staining in all OA tissue exposed to IL-1β, from 
80.1 ± 13.2 (basal) down to 55.6 ± 18.5 (IL-1β only). 
 
Co-stimulation with NaSH or GYY4137 reduced PAS staining almost to baseline (<10%), 
evidencing no clear differences in different doses nor in using NaSH or GYY4137 (Fig. 2C3–6 and 
Table 2). As for the AB staining, there seems to be a recovery with all the conditions tested. 
4.2.4. Masson's trichrome 
OA cartilage stimulated with IL-1β was only slightly less positive than the unstimulated condition 
(79.8 ± 7.4%, Fig. 2D2 and 91.0 ± 3.8%, Fig. 2D1, respectively), and adding different concentrations 
of NaSH or GYY4137 completely prevented this loss. 
4.3. Immunohistochemical analyses 
4.3.1. Matrix proteins 
Cartilage most abundant matrix proteins, col II and agg plus the main sulfated GAGs, KS and 
ChS, were also revealed and quantified with immunohistochemistry. Representative images of the 
different determinations are presented in Fig. 3. Quantification of the images was done as explained 





Fig. 3. Representative images of immunohistochemical stains performed in OA cartilage after 21 days of co-stimulation with 
IL-1β and NaSH or GYY4137 in vitro. A) Collagen type II, B) Aggrecan, C) Keratan sulfate, D) Chondroitin sulfate. Numbers 
represent the following conditions: 1) Basal, 2) Stimulation with IL-1β only, 3) IL-1β + 200 μM NaSH, 4) IL-1β + 1000 μM 
NaSH, 5) IL-1β + 200 μM GYY4137, 6) IL-1β + 1000 μM GYY4137. All size bars represent 100 μm. *p < 0.05 with respect 
to the condition with IL-1β. 
Table 3. Quantifications for the immunohistochemical determinations of collagen type II, aggrecan, keratan sulfate, and 
chondroitin sulfate performed in osteoarthritic stimulated with IL-1β. *p < 0.05 with respect to the condition with IL-1β only. 
Protein Basal 
All conditions stimulated with IL-1β (5 ng/mL) 
0 μM NaSH  GYY4137 
 
200 μM 1000 μM  200 μM 1000 μM 
        
Collagen type II 39.6 ± 7.9* 4.9 ± 1.0 49.3 ± 6.2* 54.4 ± 9.1*  31.9 ± 3.4* 56.3 ± 5.8* 
Aggrecan 29.7 ± 2.2 18.5 ± 6.7 25.6 ± 3.8 36.1 ± 2.0*  24.1 ± 5.6 30.9 ± 3.2 
Keratan sulfate 86.9 ± 21.3* 8.0 ± 5.0 82.1 ± 22.9* 84.2 ± 9.1*  69.4 ± 8.8* 87.2 ± 16.2* 
Chondroitin sulfate 94.7 ± 0.1* 13.6 ± 6.8 86.9 ± 5.4* 92.2 ± 1.1*  87.9 ± 7.1* 95.2 ± 1.1* 
        
 
The IHC analyses of col II (Fig. 3A) and agg (Fig. 3B) in the unstimulated tissue showed 
39.6 ± 7.9% and 29.7 ± 2.2% positivity, respectively and that IL-1β was responsible for significant 
losses of both cartilage ECM components, resulting in positivities of 4.9 ± 1.0% and 18.5 ± 6.7% 
respectively (Fig. 3A2 and B2, Table 3). However, when tissue was co-stimulated with NaSH or 
GYY4137 (Fig. 3A3–6 and 3B3–6), not only was their loss prevented, but levels were in fact higher 
than in the basal condition (Table 3). 
  
On the other hand, the analyses for keratan and chondroitin sulfates (Fig. 3C and D, respectively; 
and Table 3) indicated that the loss in GAGs seen with the other methods (quantification kit and S-O 
and AB stains) in the IL-1β conditions is, at least in part, due to a loss in these sulfated GAGs. 
Keratan sulfate positivity was reduced from 86.9 ± 21.5.0 to 8.0 ± 5.0 and chondroitin sulfate from 
94.7 ± 0.1 to 13.6 ± 6.8 (Basal vs IL-1β only, respectively). In both cases, the co-stimulation of IL-1β 
with NaSH or GYY4137 led to significant improvements, recovering positivity percentages similar to 
those observed in the basal condition (Fig. 3C3–6 and D3–6 and Table 3). It also stands out, again 
focusing in the inter-territorial region, that KS (and ChS to a lesser extent) production was lost in this 
area due to IL-1β, but it was recovered with the co-stimulation with NaSH or GYY4137. 
4.3.2. Metalloproteinases 
In addition, we also performed MMP3 and 13 IHCs in the cartilage disks (Fig. 4A and B, 
respectively, and Table 4). With respect to MMP3, the protein was already present in the basal 
condition (4.0 ± 1.0%), although the positivity was low (Fig. 4A1) and it increased markedly after 
exposure to IL-1β (84.2 ± 8.2%, Fig. 4A2). Co-stimulation with NaSH or GYY4137 caused an 
attenuation of this effect in all cases but only 1000 μM NaSH (41.4 ± 7.3%), 200 μM GYY4137 
(33.2 ± 2.9%) and 1000 μM GYY4137 (12.5 ± 3.5%) were significantly lower (p < 0.05). On the 
other hand, positivity inside the cells was only abated with the highest concentration (Fig. 4A4 and 
6). In the case of MMP13, its presence in the basal condition was very low (40.5 ± 0.2% Fig. 4B1, 
Table 4) but, chondrocytes actively synthesized this collagenase as a result of IL-1β stimulation 
(10.4 ± 3.2%, Fig. 4B2) and GYY4137 was more effective in counteracting this effect (200 μM: 
0.3 ± 0.1% and 1000 μM: 1.0 ± 0.5%) than NaSH (200 μM: 7.6 ± 3.6% and 1000 μM: 4.3 ± 0.1%), 




Fig. 4. Representative images of immunohistochemical stains performed in OA cartilage after 21 days of co-stimulation with 
IL-1β and NaSH or GYY4137 in vitro. A) Matrix metalloproteinase 3, B) Matrix metalloproteinase 13. Numbers represent the 
following conditions: 1) Basal, 2) Stimulation with IL-1β only, 3) IL-1β + 200 μM NaSH, 4) IL-1β + 1000 μM NaSH, 5) IL-
1β + 200 μM GYY4137, 6) IL-1β + 1000 μM GYY4137. All size bars represent 100 μm. *p < 0.05 with respect to the 
condition with IL-1β. 
  
Table 4. Quantifications for the immunohistochemical determinations of matrix metalloproteinases (MMP) 3 and 13 
performed in osteoarthritic cartilage stimulated with IL-1β. *p < 0.05 with respect to the condition with IL-1β only. 
Protein Basal 
All conditions stimulated with IL-1β (5 ng/mL) 
0 μM NaSH  GYY4137 
 
200 μM 1000 μM  200 μM 1000 μM 
        
MMP3 4.0 ± 1.0* 84.2 ± 8.2 77.8 ± 5.8 41.4 ± 7.3*  33.2 ± 2.9* 12.5 ± 3.5* 
MMP13 0.5 ± 0.2* 10.4 ± 3.2 7.6 ± 3.6 4.3 ± 0.1*  0.3 ± 0.1* 1.0 ± 0.5* 
        
 
5. Discussion 
The present work evaluated the effects of H2S-releasing compounds, NaSH and GYY4137 on the 
anabolic-catabolic balance of MEC components in OA cartilage stimulated with IL-1β. We looked at 
the release of GAGs from tissue disks with a GAG quantification kit and other matrix proteins 
through histology and immunohistochemistry. This is the first study that we know of that investigated 
the involvement of H2S in these aspects of OA progression directly on human cartilage tissue. 
 
Proper maintenance of hyaline articular cartilage relies on a balance between the anabolic and 
catabolic processes in chondrocytes. With the onset of OA, this balance is lost and cartilage 
degradation supersedes its synthesis. Predictably, all assays performed in the present study 
demonstrated that long-term stimulation with the pro-inflammatory cytokine IL-1β results in loss of 
the main matrix components, i.e. collagen type II, aggrecan, hyaluronic acid, and sulfated GAGs. 
Through the GAGs quantification assay, the S-O and TB stains, and KS/ChS IHCs it was shown that 
co-stimulation with H2S-forming reagents partially, or even completely in some cases, avoided GAGs 
destruction. We came across one exception; S-O staining for 200 μM NaSH suggested this 
concentration might be detrimental. In our opinion, this is an individual result that is refuted by the 
rest of the findings that support the protection of GAGs with 200 μM NaSH. 
 
As for the content of col II, the MT staining was not very informative. Qualitatively, the 
histologic results did not indicate major differences in col II content between the various conditions. 
However, the col II IHC allowed us to quantitatively assert a significant recovery with both sulfide 
compounds. 
 
In our opinion, results also indicate that NaSH and GYY4137 might have pro-anabolic effects. In 
some of the histological stains and IHCs, positivity inside the cells and/or the inter-territorial zone 
was lost, suggesting that active synthesis by the cells was inhibited by IL-1β. This was recovered 
with the H2S-forming compounds. Further, according to the IHCs, col II and agg were not only 
recovered but even promoted. Strictly speaking, we cannot tell if H2S is simply protecting matrix 
degradation or if it is, in addition, inducing the synthesis of matrix proteins by the chondrocytes. 
However, quantification of the images and the mentioned effects in the intra-cellular and inter-
territorial regions seem to suggest the latter. 
 
Another noteworthy finding is the increased presence of carbohydrates in the tissue, revealed in 
the PAS stain, that is further increased after 21 days of stimulation with IL-1β. This could be related 
to a change towards a lipidic metabolism in chondrocytes which has been linked to the development 
of OA [19,20]. This increase in carbohydrates effectively disappears in the presence of NaSH or 
GYY4137, thus these compounds may also protect against this phenotypic change. 
  
With respect to the catabolic enzymes, the present results also demonstrated clear protective 
effects against the increased MMPs levels. IHCs for MMP3 and 13 also showed a significant increase 
with stimulation with IL-1β and were subsequently reduced with the co-stimulation with sulfide 
compounds, especially at the highest dose of GYY4137. The present results are in line with others 
previously published by our group [15]. We showed that 48 h co-stimulation with NaSH and 
GYY4137 had anti-catabolic effects in IL-1β stimulated OA chondrocytes. We observed a dose-
dependent reduction of gene expression of MMP3 and 13, with both compounds. This also 
corresponded with a reduction in protein levels, evidenced both with IHC and, in the case of MMP13, 
an ELISA. Here we demonstrate that this protective effect against MMPs is maintained over time and 
directly in cartilage tissue in vitro. 
 
It is also known that IL-1β stimulates the release of ADAMTSs (a disintegrin and 
metalloproteinase with trombospondin motifs) 4 and 5 [21], responsible of the segmentation of 
proteoglycans such as aggrecan and versican [22]. In the tissue used in our study, apart from the 
overproduction of metalloproteinases, there surely also was an increase in these aggrecanases, 
reflected by the loss of cartilage GAGs from the discs and the agg IHC. However, in the conditions 
treated with H2S, loss of GAGs to supernatants was reduced, and aggrecan in the disks was 
preserved. So although we have no direct evidence, these results suggest that sulfide compounds were 
also capable of inhibiting the induction of aggrecanases, or of protecting against their effects, 
resulting in the protection of cartilage. 
 
It has been demonstrated that chondrocytes' catabolic predisposition begins with an increase in 
aggrecanases followed by an increase in MMPs [23,24]. In general, there is a consensus that while 
aggrecan degradation in the ECM is a reversible process, induction of MMPs eventually leads to 
irreversible degradation of collagen type II [25], and an effective treatment needs to be able to revert 
the catabolic chondrocyte phenotype. Therefore, the present results suggest that exogenous 
administration of H2S might be effective in accomplishing this, stopping the perpetuation of the 
catabolic phenotype in the cells. 
 
There is, to date, no publication that we know of that analysed the effects of NaSH or GYY4137 
on human OA cartilage degradation. Some studies can be found that look at the effects of H2S 
sources in in vivo models of acute inflammation. The effects of GYY4137 [16], Na2S [26] and 
Lawesson's reagent [27] were evaluated on signs and/or markers of inflammation, oxidative stress or 
pain in the joints of the animals, but none of these studies looked at long term effects on cartilage. 
On the other hand, a report evaluated the effects of diallyl sulfide (DAS), an oil-soluble 
organosulphur compound extracted from garlic, in a mechanical model of OA in rabbits [28]. DAS 
treatment significantly reduced the total Mankin Score with respect to the vehicle treated group at 
week 9, as well as MMP1, MMP3, MMP13 and IL-1β gene expression in the DAS-treated cartilage. 
Notably, Benavides et al. [29] showed that garlic-derived organic polysulfides can be converted into 
hydrogen sulfide through a glucose-supported glutathione-dependent reaction and, importantly, that 
the cardiovascular protection attributed to garlic is in fact mediated by H2S. 
 
Hydrogen sulfide has also been linked to the inhibition of fibrosis in several pathologies, such as 
lung, liver, kidney and heart fibrosis [30]. Zhang and co-workers attribute these effects to H2S anti-
oxidant, anti-apoptotic, anti-inflammatory, pro-angiogenic properties and its ability to inhibit 
fibroblast activation and speculate that H2S will likely play a role in all kinds of fibrosis in the body. 
Cartilage might well be one example. The attempts by chondrocytes to repair damaged tissue result in 
the formation of fibro-cartilage, which does not have the same mechanical or compositional 
properties as hyaline cartilage [31]. 
 
Additionally, several reports have also provided evidence that H2S biosynthesis or its endogenous 
levels are reduced or correlate with disease severity in some chronic pathologies such as hypertension 
[32], type II diabetes [33] or chronic obstructive pulmonary disease [34]. With respect to OA, our 
group has some preliminary evidence that H2S biosynthesis might be reduced in the osteoarthritic 
joint [35]. We believe this might be another factor contributing to the onset of OA, though more 
research is needed in this direction. 
  
Overall, the present results indicate that hydrogen sulfide, supplied as NaSH and GYY4137, 
exerts tissue protective effects in OA cartilage stimulated with IL-lβ for 21 days in vitro. H2S appears 
to prevent the shift toward catabolic phenotype in chondrocytes and was able not only to protect 
cartilage ECM against the catabolic action potentiated by IL-lβ, but also to stimulate the synthesis of 
GAGs, aggrecan and type II collagen in cells. 
 
Therefore, exogenous supplementation with sources of H2S should be further explored as a 
therapeutic option for osteoarthritis. These might include synthetic reagents that produce H2S or 
alternatively, natural H2S sources, such as sulfurous mineral waters. A few recent randomized clinical 
trials and systematic reviews have found evidence supporting beneficial effects of balneotherapy 
using this kind of waters [36,37,38]. In this context, our results might also contribute to the 
understanding of the mechanisms responsible for these positive effects, which at present have not 
been fully elucidated [39]. It could be hypothesized that because H2S bioavailability is reduced is 
OA, exogenous supplementation, acting through anti-inflammatory, anti-catabolic, anti-oxidant 
and/or anti-fibrotic pathways results in the beneficial effects that have been demonstrated in in vitro 
and in vivo pre-clinical models and human clinical trials. 
 
More in vivo studies in OA animal models comparing for instance, intra-articular administration 
of H2S synthetic compounds to balneotherapy in sulfurous water would provide further evidence of 
efficacy and help to determine the most appropriate route of administration. 
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